Table 3.

LINE-1 methylation markers in patients receiving adjuvant chemotherapy.

First Author and Year	Tumor	Overall Population (Treated Patients)	Treatment	Samples	Markers	Methods	Response to Treatment	Other Findings
Kawakami, K., 2011 [71]	CRC	155 (94)	5-FU	Tumor tissues	LINE-1	MS-PCR and Methylight assay	LINE-1 hypomethylation conferred a survival benefit in patients receiving adjuvant therapy. Benefits from adjuvant chemotherapy were not evident in patients with LINE-1 hypermethylation	In patients treated with surgery alone, LINE-1 hypomethylation was associated with worse prognosis
Chen, D., 2016 [73]	CRC	336 (NA)	FOLFOX-4 or mFOLFOX-6	Tumor tissues	LINE-1	Pyrosequencing	LINE-1 methylation was associated with clinicopathological features and recurrence-free survival in CRC patients receiving adjuvant therapy based on the FOLFOX protocol	NA
Lou, Y.T., 2015 [74]	Colon cancer	129 (129)	FOLFOX-4	Tumor tissues	LINE-1	Pyrosequencing	LINE-1 methylation level was lower in patients receiving adjuvant therapy with post-therapeutic recurrence than in those without recurrence. LINE-1 hypomethylation as an independent risk factor of post-therapeutic recurrence	Patients with LINE-1 hypomethylation had reduced disease free survival in the whole cohort and in those with post-therapeutic recurrence after 6 months

Abbreviations: CRC, Colorectal Cancer; 5-FU, 5 fluorouracil; LINE-1, Long interspersed nuclear element-1; MS-PCR, methylation-specific PCR.